{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:03:01Z","timestamp":1780081381359,"version":"3.54.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40119-026-00450-y","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:04:25Z","timestamp":1779887065000},"page":"201-229","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Contemporary Description of Clinical Characteristics and Outcomes in Patients with Hereditary ATTR Amyloidosis: Results from the Multicountry OverTTuRe Study"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06355934","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4024-3691","authenticated-orcid":false,"given":"Kevin M.","family":"Alexander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Kohsaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen Hvitfeldt","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid J.","family":"Terkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Gustav","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krister","family":"J\u00e4rbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti Gauvri","family":"Bhimjiyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Matsue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Pilebro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"3","key":"450_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s10741-021-10080-2","volume":"27","author":"J Nativi-Nicolau","year":"2022","unstructured":"Nativi-Nicolau J, Karam C, Khella S, Maurer M. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev. 2022;27(3):785\u201393.","journal-title":"Heart Fail Rev"},{"issue":"3","key":"450_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/mus.28026","volume":"69","author":"C Karam","year":"2024","unstructured":"Karam C, Mauermann ML, Gonzalez-Duarte A, et al. Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: recommendations from a panel of experts. Muscle Nerve. 2024;69(3):273\u201387.","journal-title":"Muscle Nerve"},{"issue":"9","key":"450_CR3","doi-asserted-by":"publisher","first-page":"E2403","DOI":"10.1002\/humu.22619","volume":"35","author":"DM Rowczenio","year":"2014","unstructured":"Rowczenio DM, Noor I, Gillmore JD, et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat. 2014;35(9):E2403\u201312.","journal-title":"Hum Mutat"},{"key":"450_CR4","volume-title":"GeneReviews","author":"Y Sekijima","year":"1993","unstructured":"Sekijima Y, Nakamura K. Hereditary transthyretin amyloidosis. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews. Seattle: University of Washington; 1993."},{"issue":"5","key":"450_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/mus.26034","volume":"57","author":"HH Schmidt","year":"2018","unstructured":"Schmidt HH, Waddington-Cruz M, Botteman MF, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57(5):829\u201337.","journal-title":"Muscle Nerve"},{"key":"450_CR6","doi-asserted-by":"publisher","first-page":"1242815","DOI":"10.3389\/fneur.2023.1242815","volume":"14","author":"L Poli","year":"2023","unstructured":"Poli L, Labella B, Cotti Piccinelli S, et al. Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy. Front Neurol. 2023;14:1242815.","journal-title":"Front Neurol"},{"issue":"2","key":"450_CR7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/ane.13035","volume":"139","author":"J Finsterer","year":"2019","unstructured":"Finsterer J, Iglseder S, Wanschitz J, Topakian R, L\u00f6scher WN, Grisold W. Hereditary transthyretin-related amyloidosis. Acta Neurol Scand. 2019;139(2):92\u2013105.","journal-title":"Acta Neurol Scand"},{"issue":"Suppl 1","key":"450_CR8","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.amjmed.2022.01.006","volume":"135","author":"D Namiranian","year":"2022","unstructured":"Namiranian D, Geisler S. Neuromuscular complications of systemic amyloidosis. Am J Med. 2022;135(Suppl 1):S13\u20139.","journal-title":"Am J Med"},{"issue":"6","key":"450_CR9","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","volume":"268","author":"D Adams","year":"2021","unstructured":"Adams D, Ando Y, Beirao JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2021;268(6):2109\u201322.","journal-title":"J Neurol"},{"issue":"22","key":"450_CR10","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"450_CR11","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","volume":"126","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286\u2013300.","journal-title":"Circulation"},{"issue":"11_Supplement","key":"450_CR12","doi-asserted-by":"publisher","first-page":"A890","DOI":"10.1016\/S0735-1097(18)31431-1","volume":"71","author":"I Lousada","year":"2018","unstructured":"Lousada I, Maurer M, Warner M, Guthrie S, Hsu K, Grogan M. Amyloidosis Research Consortium Cardiac Amyloidosis Survey: results from patients with AL and ATTR amyloidosis and their caregivers. JACC. 2018;71(11_Supplement):A890-A.","journal-title":"JACC"},{"issue":"5","key":"450_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1136\/jnnp-2016-315262","volume":"88","author":"A Cortese","year":"2017","unstructured":"Cortese A, Vegezzi E, Lozza A, et al. Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. J Neurol Neurosurg Psychiatry. 2017;88(5):457\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"450_CR14","doi-asserted-by":"crossref","unstructured":"Collins P, Melinis N, Chung WY, et al. Misdiagnosis rates in ATTR-CM patients and associated symptoms. Eur Heart J. 2025;46(Supplement_1):ehaf784.2706.","DOI":"10.1093\/eurheartj\/ehaf784.2706"},{"issue":"8","key":"450_CR15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00415-025-13218-6","volume":"272","author":"PE Doneddu","year":"2025","unstructured":"Doneddu PE, Moretti G, Di Stefano V, et al. Prevalence of hereditary transthyretin amyloidosis in CIDP patients with red flags: a multicenter genetic screening and misdiagnosis analysis. J Neurol. 2025;272(8):515.","journal-title":"J Neurol"},{"issue":"Suppl 2","key":"450_CR16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10072-020-04889-2","volume":"43","author":"F Manganelli","year":"2022","unstructured":"Manganelli F, Fabrizi GM, Luigetti M, Mandich P, Mazzeo A, Pareyson D. Hereditary transthyretin amyloidosis overview. Neurol Sci. 2022;43(Suppl 2):595\u2013604.","journal-title":"Neurol Sci"},{"issue":"1","key":"450_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","volume":"10","author":"MH Rozenbaum","year":"2021","unstructured":"Rozenbaum MH, Large S, Bhambri R, et al. Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review. Cardiol Ther. 2021;10(1):141\u201359.","journal-title":"Cardiol Ther"},{"issue":"4","key":"450_CR18","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/13506129.2021.1950681","volume":"28","author":"A Godara","year":"2021","unstructured":"Godara A, Riesenburger RI, Zhang DX, et al. Association between spinal stenosis and wild-type ATTR amyloidosis. Amyloid. 2021;28(4):226\u201333.","journal-title":"Amyloid"},{"issue":"11","key":"450_CR19","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.jhsa.2025.07.017","volume":"50","author":"JP Donnelly","year":"2025","unstructured":"Donnelly JP, Hanna M, Sperry BW, Seitz WH Jr. Carpal tunnel syndrome: a potential early, red-flag sign of amyloidosis. J Hand Surg Am. 2025;50(11):1370\u20138.","journal-title":"J Hand Surg Am"},{"issue":"17","key":"450_CR20","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","volume":"72","author":"BW Sperry","year":"2018","unstructured":"Sperry BW, Reyes BA, Ikram A, et al. Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J Am Coll Cardiol. 2018;72(17):2040\u201350.","journal-title":"J Am Coll Cardiol"},{"key":"450_CR21","doi-asserted-by":"publisher","first-page":"1425862","DOI":"10.3389\/fneur.2024.1425862","volume":"15","author":"D Tamasauskas","year":"2024","unstructured":"Tamasauskas D, Tamasauskiene L. Transthyretin amyloidosis in patients with spinal stenosis who underwent spinal surgery: a systematic review and meta-analysis. Front Neurol. 2024;15:1425862.","journal-title":"Front Neurol"},{"issue":"3","key":"450_CR22","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1002\/ehf2.13913","volume":"9","author":"R Lauppe","year":"2022","unstructured":"Lauppe R, Liseth Hansen J, Fornwall A, et al. Healthcare resource use of patients with transthyretin amyloid cardiomyopathy. ESC Heart Fail. 2022;9(3):1636\u201342.","journal-title":"ESC Heart Fail"},{"key":"450_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-025-00421-9","author":"J Wixner","year":"2025","unstructured":"Wixner J, Dispenzieri A, Amass L, et al. Survival in a contemporary, real-world cohort of patients with mixed-phenotype transthyretin amyloid cardiomyopathy treated with Tafamidis: an analysis from THAOS. Cardiol Ther. 2025. https:\/\/doi.org\/10.1007\/s40119-025-00421-9. (online ahead of print).","journal-title":"Cardiol Ther"},{"issue":"1","key":"450_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","volume":"29","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maurer MS, Suhr OB. THAOS\u2014The Transthyretin Amyloidosis Outcomes Survey: Initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29(1):63\u201376.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"450_CR25","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13023-023-02962-5","volume":"18","author":"L Gentile","year":"2023","unstructured":"Gentile L, Coelho T, Dispenzeri A, et al. A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Orphanet J Rare Dis. 2023;18(1):350.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"450_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13023-025-03547-0","volume":"20","author":"D Delgado","year":"2025","unstructured":"Delgado D, Dabbous F, Shivappa N, et al. Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review. Orphanet J Rare Dis. 2025;20(1):29.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"450_CR27","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1111\/ene.12225","volume":"20","author":"P Lozeron","year":"2013","unstructured":"Lozeron P, Theaudin M, Mincheva Z, et al. Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2013;20(12):1539\u201345.","journal-title":"Eur J Neurol"},{"issue":"2","key":"450_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00415-016-8337-3","volume":"264","author":"V Plant\u00e9-Bordeneuve","year":"2017","unstructured":"Plant\u00e9-Bordeneuve V, Gorram F, Salhi H, et al. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study. J Neurol. 2017;264(2):268\u201376.","journal-title":"J Neurol"},{"issue":"1","key":"450_CR29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5334\/gh.1262","volume":"18","author":"D Brito","year":"2023","unstructured":"Brito D, Albrecht FC, de Arenaza DP, et al. World Heart Federation consensus on transthyretin amyloidosis cardiomyopathy (ATTR-CM). Glob Heart. 2023;18(1):59.","journal-title":"Glob Heart"},{"issue":"3","key":"450_CR30","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40119-025-00402-y","volume":"14","author":"JD Gillmore","year":"2025","unstructured":"Gillmore JD, Hahn K, Smith JG, et al. Rationale and design of ANTHOLOGY: an ATTR Amyloidosis Real-World Evidence Program aiming to address gaps in amyloidosis care. Cardiol Ther. 2025;14(3):477\u201390.","journal-title":"Cardiol Ther"},{"key":"450_CR31","unstructured":"ClinicalTrials.gov. NCT06355934. OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis (OverTTuRe). 2024. https:\/\/clinicaltrials.gov\/study\/NCT06355934. Accessed 15 May 2024."},{"issue":"10","key":"450_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-039996","volume":"10","author":"AH Riis","year":"2020","unstructured":"Riis AH, Kristensen PK, Petersen MG, Ebdrup NH, Lauritsen SM, J\u00f8rgensen MJ. Cohort profile: CROSS-TRACKS: a population-based open cohort across healthcare sectors in Denmark. BMJ Open. 2020;10(10):e039996.","journal-title":"BMJ Open"},{"issue":"6","key":"450_CR33","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, et al. Updating and validating the Charlson Comorbidity Index and Score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"450_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jns.12153","volume":"21","author":"I Concei\u00e7\u00e3o","year":"2016","unstructured":"Concei\u00e7\u00e3o I, Gonz\u00e1lez-Duarte A, Obici L, et al. \u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5\u20139.","journal-title":"J Peripher Nerv Syst"},{"issue":"14","key":"450_CR35","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2217\/cer-2022-0074","volume":"11","author":"J Nativi-Nicolau","year":"2022","unstructured":"Nativi-Nicolau J, Fine NM, Ortiz-P\u00e9rez JT, et al. Clinical manifestations and healthcare utilization before diagnosis of transthyretin amyloidosis. J Comp Eff Res. 2022;11(14):1031\u201344.","journal-title":"J Comp Eff Res"},{"issue":"1","key":"450_CR36","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.cardfail.2024.10.223","volume":"31","author":"K Alexander","year":"2025","unstructured":"Alexander K, Dasgupta N, Mathisen J, M\u00f8ller SHG, Tvistholm A, Maurer M. Temporal trends in the incidence and prevalence of transthyretin amyloid cardiomyopathy in the USA: an observational database study. J Card Fail. 2025;31(1):268.","journal-title":"J Card Fail"},{"issue":"1","key":"450_CR37","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s13023-023-02933-w","volume":"18","author":"T Damy","year":"2023","unstructured":"Damy T, Bourel G, Slama M, et al. Incidence and survival of transthyretin amyloid cardiomyopathy from a French nationwide study of in- and out-patient databases. Orphanet J Rare Dis. 2023;18(1):345.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"450_CR38","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.cjco.2025.03.002","volume":"7","author":"N Fine","year":"2025","unstructured":"Fine N, Ducharme A, Matte G, Mezei M, Bril V, Delgado D. Diagnosis and management of mixed phenotype hereditary transthyretin amyloidosis: a case-based, Canadian perspective. CJC Open. 2025;7(5):614\u201327.","journal-title":"CJC Open"},{"issue":"1","key":"450_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16\u201326.","journal-title":"Circulation"},{"issue":"1","key":"450_CR40","doi-asserted-by":"publisher","first-page":"P22","DOI":"10.1186\/1750-1172-10-S1-P22","volume":"10","author":"I Lousada","year":"2015","unstructured":"Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Patient experience with hereditary and senile systemic amyloidoses: a survey from the Amyloidosis Research Consortium. Orphanet J Rare Dis. 2015;10(1):P22.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"450_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14797\/mdcvj.1163","volume":"18","author":"T Martyn","year":"2022","unstructured":"Martyn T, Rubio AC, Estep JD, Hanna M. Opportunities for earlier diagnosis and treatment of cardiac amyloidosis. Methodist Debakey Cardiovasc J. 2022;18(5):27\u201339.","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"11","key":"450_CR42","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(11):1076\u2013126.","journal-title":"J Am Coll Cardiol"},{"key":"450_CR43","doi-asserted-by":"publisher","first-page":"B99","DOI":"10.1093\/eurheartjsupp\/suad082","volume":"25","author":"M Mallus","year":"2023","unstructured":"Mallus M, Rizzello V. Treatment of amyloidosis: present and future. Eur Heart J Suppl. 2023;25:B99\u2013103.","journal-title":"Eur Heart J Suppl"},{"issue":"3","key":"450_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/egastro-2025-100198","volume":"3","author":"I Anan","year":"2025","unstructured":"Anan I. Advances in the treatment of transthyretin amyloidosis. eGastroenterology. 2025;3(3):e100198.","journal-title":"eGastroenterology"},{"issue":"1","key":"450_CR45","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","volume":"15","author":"P Elliott","year":"2022","unstructured":"Elliott P, Drachman BM, Gottlieb SS, et al. Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail. 2022;15(1):e008193.","journal-title":"Circ Heart Fail"},{"issue":"2","key":"450_CR46","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161\u201372.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"450_CR47","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","volume":"6","author":"G Merlini","year":"2013","unstructured":"Merlini G, Plante-Bordeneuve V, Judge DP, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013;6(6):1011\u201320.","journal-title":"J Cardiovasc Transl Res"},{"issue":"2","key":"450_CR48","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s40120-021-00258-z","volume":"10","author":"M Waddington-Cruz","year":"2021","unstructured":"Waddington-Cruz M, Wixner J, Amass L, et al. Characteristics of patients with late- vs. early-onset Val30Met transthyretin amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Neurol Ther. 2021;10(2):753\u201366.","journal-title":"Neurol Ther"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00450-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00450-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00450-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T18:02:06Z","timestamp":1780077726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-026-00450-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["450"],"URL":"https:\/\/doi.org\/10.1007\/s40119-026-00450-y","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kevin Alexander is a consultant to Alexion, Alnylam, Bayer, BridgeBio, Novo Nordisk, and Pfizer. Kevin Alexander is also an Editorial Board member of\n                      Cardiology and Therapy\n                      . He was not involved in the selection of peer reviewers for the manuscript nor in any of the subsequent editorial decisions. Shun Kohsaka has received investigator-initiated research funding from Novartis and AstraZeneca. Steen Hvitfeldt Poulsen has received consulting fees from BridgeBio; Pfizer, Alnylam, Novo Nordisk, Cytokinetics, Bayer and AstraZeneca. Astrid Terkelsen has received honorarium from Novo Nordisk DK, Sanofi, AstraZeneca, and Alnylam Sweden AB. J. Gustav\u00a0Smith reports that his employer (Gothenburg University) is paid by AstraZeneca for his involvement in ANTHOLOGY (no personal payment). Johan Sundstr\u00f6m reports direct or indirect stock ownership in companies (Sence Research AB, Symptoms Europe AB, MinForskning AB, Anagram kommunikation AB) providing services to companies and authorities in the health sector, including Amgen, AstraZeneca, Bayer, Boehringer, Eli Lilly, Gilead, GSK, G\u00f6teborg University, Itrim, Ipsen, Janssen, Karolinska Institutet, LIF, Link\u00f6ping University, Novo Nordisk, Parexel, Pfizer, Region Stockholm, Region Uppsala, Sanofi, STRAMA, Takeda, TLV, Uppsala University, Vifor Pharma, WeMind. Jason Wright, Arti Gauvri Bhimjiyani, Krister J\u00e4rbrink\n                      \u2020\n                      , and Laura Davis are employees of, and hold stock in, AstraZeneca. Lisa Anderson has participated in an advisory board for Alnylam and has received travel support from Abbott and support as a Junior Fellow from Pfizer. Yuya Matsue has received honorarium from Otsuka Pharmaceutical Co., Ltd., EN Otsuka Pharmaceutical Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., AstraZeneca, Nippon Boehringer Ingelheim Co., Ltd., Bayer Yakuhin, Ltd., Kyowa Kirin Co., Ltd., Pfizer Japan Inc., and Alnylam Japan. He has also received collaborative research funding from Otsuka Pharmaceutical Co., Ltd., EN Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Bayer Yakuhin, Ltd., Nippon Boehringer Ingelheim Co., Ltd., AstraZeneca K.K., Roche Diagnostics K.K., Grace Imaging Inc., and Omron Healthcare Co., Ltd. Bj\u00f6rn Pilebro has received financial reimbursement for consulting from AstraZeneca and is an investigator in studies sponsored by Akcea Therapeutics, Alnylam Pharmaceuticals, Inc., and Intellia Therapeutics. Krister J\u00e4rbrink was an employee and shareholder of AstraZeneca at the time of the study but has since changed employment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"OverTTuRe was performed in accordance with ethical principles that are consistent with the Declaration of Helsinki, International Conference on Harmonization (ICH), Good Clinical Practices (GCPs), Guidelines for Good Pharmacoepidemiology Practices (GPP), and the applicable legislation on noninterventional studies and\/or observational studies. Obtaining informed consent from participants was not applicable as this study was solely based on secondary data from the following data sources: Optum\u2019s de-identified Clinformatics\n                      \u00ae\n                      Data Mart Database (Optum\n                      \u00ae\n                      CDM) from the United States, Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES) from the United Kingdom, Medical Data Vision (MDV) from Japan, CROSS-TRACKS from Denmark, and CELOSIA from Sweden. Ethical approval for the use of CELOSIA data in the OverTTuRe study was granted by the Swedish Ethical Review Authority. CPRD\u2019s Research Data Governance approved the use of CPRD and HES data in the OverTTuRe study. The MDV utilizes anonymized data, which exempts clinical studies from the application of the Japanese Ethical Guidelines for Medical and Biological Research Involving Human Subjects. In this study, MDV anonymized the provided data; therefore, obtaining informed consent was deemed unnecessary. In Denmark, register-based studies require no ethical approval [\n                      \n                      ]. Optum\n                      \u00ae\n                      CDM does not require ethics approval, as the data is de-identified and fully compliant with the Health Insurance Portability and Accountability Act.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}